Fast detection of DNA of hepatitis B virus by real time PCR

90 blood plasma samples from patients with suspected chronic viral hepatitis B (CVHB) were analyzed by real-time polymerized chain reaction (PCR). The findings were compared with the results obtained by 2 PCR electrophoresis-based test-systems; the sensitivity limit for the quantification of DNA of hepatitis B virus (HBV) was determined; in the present case, the limit corresponded to 30 replications of HBV DNA to reaction (600 GE/ml). The positive result of real-time PCR was registered in 53.3% of cases. The quantity of HBV DNA replications in blood plasma samples varied from 30 to 3.9 x 10(6) per reaction (600-7.8 x 10(7) GE/ml). Serological profiles were analyzed in 18 patients with the verified diagnosis of CVHB. HBV DNA was detected in blood of 65% of HBsAg(+)-patients. The markers of HBeAg replication were noted in 35.5% of patients; it is noteworthy, that HBeAg(+)-samples were characterized by a higher level of viral loads (> or = 10(6) GE/ml) versus HBeAg(-)-samples (> or = 6 x 10(3) GE/ml). An analysis of blood-plasma samples dynamically obtained from one patient with chronic renal insufficiency and CVHB showed a decreased level of viral load from 1.7 x 10(7) GE/ml to a negative finding of real-time PCR registered after a therapy course by zeffix. Hence, the automated and standardized real-time PCR, when used at a multi-field patient-care facility, ensures a better diagnosis of viral hepatitis B.     

Design of an immunochip for separate detection of hepatitis C virus antibodies

A test kit as an immunochip designed for the diagnosis of hepatic C virus (HCV) has a high sensitivity and specificity. Recombinant HCV antigens were separately immobilized on the activated slides together with internal controls. Serum test results were red by ScanArray Express. K-factor and corresponding value of cut-off were calculated for each antigen and internal controls. Comparative evaluation of the sensitivity and specificity of the immunochip was carried out by commercial ELISA test kits and linear blotting analyses on 448 blood samples containing and free from NCV antibodies.     

Evaluation of the first domestic immunoenzyme recombinant test-system "Khlami-IGA-DS-Tr" for detection of class A antibodies to Chlamydia trachomatis

A test system for detecting species-specific class A antibodies to Chlamydia trachomatis, making use of recombinant chlamydial antigen, is developed in Russia for the first time. Its efficiency was demonstrated in blind clinical trials. The sensitivity, specificity, activity, and use of Chlamy-IgA-DC-Tr test system are not inferior to foreign analogs.     

RT-PCR-based evaluation of the activity of human papilloma virus infection in relapsing papillomatosis of the larynx

RT-PCR-based examination of papilloma samples obtained from patients with relapsing papillomatosis of the larynx showed an incidence rate of human papilloma virus (HPV) amounting to 89%. The viral load level of the studied samples, when measured by concurrent RT-PCR HPV, differed by more than 130 times. It made, in the untreated patient, 1.2 x 10(9) hormonal equivalents/ml, i.e. 13-fold higher versus the patient who received pathogenetic therapy. Thus, the approach in question provides for a possibility to monitor the activity of papilloma viral infection and to evaluate the efficiency of different variations of pathogenetic therapy because the "classic" variant of PCR-detection is not informative in the discussed case.